

# Thomas Eigentler

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7190322/thomas-eigentler-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236  
papers

10,420  
citations

49  
h-index

97  
g-index

293  
ext. papers

12,651  
ext. citations

4  
avg, IF

5.96  
L-index

#	Paper	IF	Citations
236	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2022</b> , 1	4.9	0
235	Cutaneous Melanoma. <i>Pediatric Oncology</i> , <b>2022</b> , 487-510	0.5	
234	Genome-Wide Association Study Suggests the Variant rs7551288*A within the DHCR24 Gene Is Associated with Poor Overall Survival in Melanoma Patients. <i>Cancers</i> , <b>2022</b> , 14, 2410	6.6	0
233	Skin Cancer in Childhood and Adolescents: Treatment and Implications for the Long-Term Follow-Up <b>2021</b> , 349-355		0
232	A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma <b>2021</b> , 9,		1
231	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 765608	5.3	1
230	Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 643156	5.3	3
229	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 170-181	7.5	11
228	TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9524-9524	2.2	
227	Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9516-9516	2.2	6
226	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 1-10	7.5	4
225	Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9545-9545	2.2	5
224	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 61-75	7.5	5
223	Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma. <i>Acta Radiologica</i> , <b>2021</b> , 2841851211019808	2	1
222	Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , <b>2021</b> , 68 Suppl 4, e28992	3	3
221	Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) <b>2021</b> ,		11
220	Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1263-1275	7.4	1

219	Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1089-1099	7.4	1
218	Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. <i>Targeted Oncology</i> , <b>2021</b> , 16, 197-205	5	5
217	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
216	1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study. <i>Annals of Oncology</i> , <b>2020</b> , 31, S745	10.3	2
215	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1558-1568	40	100
214	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2543-2551	2.2	13
213	Quality assurance in melanoma care: guideline-based quality indicators for melanoma - implementation, evaluation and update process. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 848-857	1.2	2
212	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing <b>2020</b> , 8,		53
211	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1835-1844	40	204
210	Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. <i>Nature Communications</i> , <b>2020</b> , 11, 1335	17.4	33
209	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 275-294	1.2	25
208	Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 1968-1975	4.3	9
207	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2021-2025	4.6	6
206	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 400-413	1.2	19
205	Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
204	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients <b>2020</b> , 8,		27
203	Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. <i>Australasian Journal of Dermatology</i> , <b>2020</b> , 61, e310-e318	1.3	4
202	Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial <b>2020</b> ,		7

201	Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10070-10070	2.2	3
200	Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer. <i>Acta Dermato-Venereologica</i> , <b>2020</b> , 100, adv00328	2.2	2
199	Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10073-10073	2.2	0
198	A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3096-3096	2.2	4
197	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa140	0.9	3
196	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive F-FDG-PET. <i>Theranostics</i> , <b>2020</b> , 10, 925-937	12.1	26
195	Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. <i>European Journal of Cancer</i> , <b>2020</b> , 125, 38-45	7.5	15
194	Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 136-139	1.2	3
193	Late recurrence of melanoma after 10 years - Is the course of the disease different from early recurrences?. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 977-983	4.6	1
192	CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases. <i>European Journal of Radiology</i> , <b>2020</b> , 131, 109242	4.7	1
191	Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. <i>American Journal of Pathology</i> , <b>2020</b> , 190, 2155-2164	5.8	2
190	Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknesses. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 682-690	1.2	1
189	Melanoma brain metastases - Interdisciplinary management recommendations 2020. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 89, 102083	14.4	25
188	Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. <i>Annals of Internal Medicine</i> , <b>2020</b> , 172, 836-837	8	25
187	The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2183-2197	4.6	10
186	Simultaneous targeted therapy for metastatic melanoma and hepatitis C. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 42-43	1.2	1
185	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1547-1559	7.4	23
184	Targeted Therapy in Advanced Melanoma With Rare Mutations. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3142-3151	2.2	43

183	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , <b>2019</b> , 116, 207-215	7.5	26
182	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. <i>ESMO Open</i> , <b>2019</b> , 4, e000491	6	71
181	S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2019</b> , 17, 562-577	1.2	3
180	Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. <i>Cancer Imaging</i> , <b>2019</b> , 19, 31	5.6	25
179	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2019</b> , 17, 562-576	1.2	10
178	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1299-1307.e7	4.5	4
177	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 867-875	2.2	135
176	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221301	3.7	9
175	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study <b>2019</b> , 7, 180		74
174	5. Netzwerktreffen der zertifizierten Hautkrebszentren. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2019</b> , 17, 763-764	1.2	
173	Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy. <i>Annals of Oncology</i> , <b>2019</b> , 30, v559	10.3	2
172	Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). <i>Annals of Oncology</i> , <b>2019</b> , 30, v903-v904	10.3	3
171	Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal antiPD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). <i>Annals of Oncology</i> , <b>2019</b> , 30, v536-v537	10.3	3
170	Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. <i>European Journal of Radiology</i> , <b>2019</b> , 121, 108688	4.7	10
169	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study <b>2019</b> , 7, 299		52
168	Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2019</b> , 17, 999-1004	1.2	4
167	The Systemic Treatment of Melanoma. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2019</b> , 116, 497-504		6
166	Medical treatment of advanced cutaneous squamous-cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33 Suppl 8, 38-43	4.6	35

165	Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. <i>Immunotherapy</i> , <b>2019</b> , 11, 297-309	3.8	16
164	Time trends in incidence and mortality of cutaneous melanoma in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 1272-1280	4.6	29
163	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 825-834	7.4	63
162	Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 478-485	4	12
161	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1403-1414	11.5	44
160	Safety of shortened infusion times for combined ipilimumab and nivolumab. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 135-140	7.4	2
159	Patient acceptance and trust in automated computer-assisted diagnosis of melanoma with dermatofluoroscopy. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2018</b> , 16, 854-859	1.2	7
158	Patientenakzeptanz und -vertrauen in die automatisierte, computergestützte Diagnostik des Melanoms mithilfe der Dermatofluoroskopie. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2018</b> , 16, 854-860	1.2	5
157	Vemurafenib. <i>Recent Results in Cancer Research</i> , <b>2018</b> , 211, 77-89	1.5	26
156	Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9527-9527	2.2	14
155	Melanom der Vulva <b>2018</b> , 155-173		
154	Melanom der Vagina <b>2018</b> , 273-281		
153	Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma. <i>European Radiology</i> , <b>2018</b> , 28, 1456-1464	8	5
152	Aktuelle Immuntherapien des malignen Melanoms. <i>Im Focus Onkologie</i> , <b>2018</b> , 21, 44-51	0	
151	Lymph node dissection for melanoma using tumescence local anaesthesia: an observational study. <i>European Journal of Dermatology</i> , <b>2018</b> , 28, 177-185	0.8	9
150	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , <b>2018</b> , 98, 10-16	7.5	34
149	Aktuelle Immuntherapien des malignen Melanoms. <i>Hautnah Dermatologie</i> , <b>2018</b> , 34, 32-38	0	
148	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 339-346	8.7	55

147	Self-detection frequency and recognition patterns in medium to high-risk cutaneous melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2017</b> , 15, 61-67	1.2	2
146	GSTP1 does not modify MC1R effects on melanoma risk. <i>Experimental Dermatology</i> , <b>2017</b> , 26, 730-733	4	9
145	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 57, 36-49	14.4	185
144	Aktuelle Systemtherapie des metastasierten malignen Melanoms. <i>Aktuelle Dermatologie</i> , <b>2017</b> , 43, 133-138		
143	S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2017</b> , 15, e1-e41	1.2	19
142	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 56-65	7.5	109
141	Impact of F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1312-1318	8.8	19
140	Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 703-708	4.9	4
139	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 441-449	7.4	22
138	The tanning habits and interest in sunscreen of Google users: what happened in 12 years?. <i>Photodermatology Photoimmunology and Photomedicine</i> , <b>2017</b> , 33, 68-74	2.4	11
137	Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 1860-1867	4.3	78
136	The need for psycho-oncological support for melanoma patients: Central role of patients' self-evaluation. <i>Medicine (United States)</i> , <b>2017</b> , 96, e7987	1.8	7
135	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). <i>Klinische Padiatrie</i> , <b>2017</b> , 229, 322-328	0.9	13
134	Aktuelle Immuntherapien des malignen Melanoms. <i>Info Onkologie</i> , <b>2017</b> , 20, 16-20		
133	Das Interesse an Solarien und Sonnenschutz im deutschsprachigen Raum. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2017</b> , 15, 1192-1198	1.2	
132	Pembrolizumab-induced hepatitis: diagnosis and treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2017</b> , 15, 933-935	1.2	3
131	Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 2570-2577	4.3	19
130	Type 1 diabetes mellitus caused by treatment with low-dose interferon- $\beta$ in a melanoma patient. <i>Melanoma Research</i> , <b>2017</b> , 27, 516-518	3.3	6

129	Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 2309-2315	4.3	67
128	Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. <i>Melanoma Research</i> , <b>2017</b> , 27, 321-325	3.3	35
127	Häufigkeit und Muster der Tumorerkennung nach Selbstuntersuchung bei Mittel- bis Hochrisiko-Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2017</b> , 15, 61-69	1.2	
126	Imaging characteristics of cardiac metastases in patients with malignant melanoma. <i>Cancer Imaging</i> , <b>2017</b> , 17, 19	5.6	8
125	Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. <i>European Radiology</i> , <b>2017</b> , 27, 2538-2545	8	6
124	Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 533-540	4.9	35
123	Interest in tanning beds and sunscreen in German-speaking countries. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2017</b> , 15, 1192-1198	1.2	4
122	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , <b>2017</b> , 8, 79731-79741	3.3	59
121	Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 910-6	1.2	8
120	Adjuvant treatment with pegylated interferon $\alpha$ versus low-dose interferon $\alpha$ in patients with high-risk melanoma: a randomized phase III DeCOG trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1625-32	10.3	15
119	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5818-5828	12.9	53
118	Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , <b>2016</b> , 65, 951-9	7.4	40
117	CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. <i>European Journal of Radiology</i> , <b>2016</b> , 85, 732-8	4.7	26
116	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2908-18	12.9	372
115	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 45, 7-18	14.4	264
114	Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 482-8	8.8	27
113	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. <i>Oncotarget</i> , <b>2016</b> , 7, 36130-36137	3.3	8
112	Zweites Netzwerktreffen der zertifizierten Hauttumorzentren. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 1051-1052	1.2	



111	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , <b>2016</b> , 60, 210-25	7.5	391
110	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , <b>2016</b> , 60, 190-209	7.5	412
109	Aktuelle Systemtherapie des metastasierten malignen Melanoms [Zielgerichtete Therapien und Immuntherapie als vielversprechende Optionen. <i>Kliniker</i> , <b>2016</b> , 45, 202-207	0	
108	Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 910-5	1.2	4
107	Targeted Therapies for Melanoma <b>2015</b> , 1529-1541		
106	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 908-18	21.7	1151
105	443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 861-8	7.5	37
104	Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 653-67	7.5	36
103	Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 4073-80	3.1	21
102	Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment. <i>International Journal of Dermatology</i> , <b>2015</b> , 54, 419-23	1.7	
101	Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1646-1650	4	3
100	Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 926-32	4	9
99	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 351	8.5	47
98	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1075-82	7.4	12
97	In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. <i>Pigment Cell and Melanoma Research</i> , <b>2014</b> , 27, 671-3	4.5	22
96	Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. <i>Melanoma Management</i> , <b>2014</b> , 1, 115-125	2.1	1
95	Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e86194	3.7	35
94	BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. <i>PLoS ONE</i> , <b>2014</b> , 9, e89218	3.7	16

93	Vemurafenib. <i>Recent Results in Cancer Research</i> , <b>2014</b> , 201, 215-25	1.5	23
92	Epidemiology of skin cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2014</b> , 810, 120-40	3.6	291
91	Limited efficacy of intratumoral IL-2 applied to large melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 1231-2	7.4	4
90	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 668-78	12.5	66
89	Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. <i>Journal of Immunotherapy</i> , <b>2014</b> , 37, 374-81	5	19
88	Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4390-9	12.9	30
87	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9031-9031	2.2	2
86	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9041-9041	2.2	2
85	Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)Decog-trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9071-9071	2.2	1
84	Proliferative activity, chromosomal aberrations, and tumor-specific mutations in the differential diagnosis between blue nevi and melanoma. <i>American Journal of Pathology</i> , <b>2013</b> , 182, 640-5	5.8	32
83	New landscape in the treatment of melanoma: a 2012 update. <i>Oncologie</i> , <b>2013</b> , 15, 71-77	1	1
82	Protein kinase inhibitors in melanoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2195-201	4	7
81	Effective combination of photodynamic therapy and imiquimod 5% cream in the treatment of actinic keratoses: three cases. <i>BioMed Research International</i> , <b>2013</b> , 2013, 102698	3	7
80	S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. <i>Melanoma Research</i> , <b>2013</b> , 23, 396-401	3.3	22
79	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , <b>2013</b> , 2, 76-85	4.8	102
78	Malignes Melanom S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms□JDDG - <i>Journal of the German Society of Dermatology</i> , <b>2013</b> , 11, 1-126	1.2	3
77	Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2013</b> , 11 Suppl 6, 1-116, 1-126	1.2	79
76	S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2013</b> , 11, 563-602	1.2	29

75	Brief S2k guidelines--Cutaneous squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2013</b> , 11 Suppl 3, 37-45, 39-47	1.2	33
74	Molekulargenetische Klassifikation schwieriger melanozytärer Tumoren. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2013</b> , 11, 12-19	1.2	1
73	Molecular genetic classification of difficult melanocytic tumors. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2013</b> , 11 Suppl 4, 11-8	1.2	6
72	Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e63137	3.7	18
71	Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour. <i>PLoS ONE</i> , <b>2013</b> , 8, e66953	3.7	18
70	Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. <i>PLoS ONE</i> , <b>2013</b> , 8, e81624	3.7	48
69	The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e20050-e20050	2.2	2
68	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. <i>PLoS ONE</i> , <b>2013</b> , 8, e53745	3.7	343
67	Comparison and evaluation of the current staging of cutaneous carcinomas. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2012</b> , 10, 579-86	1.2	26
66	Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 37-45	4.5	62
65	Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome. <i>Journal of Cutaneous Pathology</i> , <b>2012</b> , 39, 1088-93	1.7	22
64	Prognosis of sentinel node staged patients with primary cutaneous melanoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e29791	3.7	12
63	Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26, 48-53	4.6	35
62	Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 422-8	8.7	102
61	CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 299-303	4.3	16
60	Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1835-41	2.2	99
59	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8526-8526	2.2	
58	Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e19031-e19031	2.2	

57	A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1977-89	7.5	47
56	Health-related quality of life before and during adjuvant interferon- $\alpha$ treatment for patients with malignant melanoma (DeCOG-trial). <i>Journal of Immunotherapy</i> , <b>2011</b> , 34, 403-8	5	29
55	Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. <i>Melanoma Research</i> , <b>2011</b> , 21, 244-52	3.3	29
54	Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. <i>Melanoma Research</i> , <b>2011</b> , 21, 228-34	3.3	25
53	Oncogenetics of melanoma: basis for molecular diagnostics and therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2011</b> , 9, 510-6	1.2	1
52	Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2011</b> , 9, 690-9	1.2	20
51	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 487-93	7.4	42
50	Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. <i>Cancer</i> , <b>2011</b> , 117, 1697-703	6.4	98
49	Systematic review of medical treatment in melanoma: current status and future prospects. <i>Oncologist</i> , <b>2011</b> , 16, 5-24	5.7	394
48	A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7732-42	12.9	116
47	Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. <i>PLoS ONE</i> , <b>2011</b> , 6, e16882	3.7	17
46	Determinants of survival in patients with brain metastases from cutaneous melanoma. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 1213-8	8.7	130
45	Efficacy of low-dose interferon $\alpha$ 2a 18 versus 60 months of treatment in patients with primary melanoma of $\geq 1.5$ mm tumor thickness: results of a randomized phase III DeCOG trial. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 841-6	2.2	65
44	Melanoma staging: facts and controversies. <i>Clinics in Dermatology</i> , <b>2010</b> , 28, 275-80	3	18
43	Incisional biopsy and melanoma prognosis: Facts and controversies. <i>Clinics in Dermatology</i> , <b>2010</b> , 28, 316-8	3	64
42	Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. <i>Clinics in Dermatology</i> , <b>2010</b> , 28, 311-5	3	16
41	Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon- $\alpha$ treatment in patients with malignant melanoma: results from the multicenter DeCOG trial. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 106-14	5	30
40	Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 129-37	3.1	38

39	Systemische Therapie des metastasierten Melanoms. <i>Onkologe</i> , <b>2010</b> , 16, 1160-1166	0.1	1
38	Nachsorge des Melanoms [neue Aspekte. <i>Onkologe</i> , <b>2010</b> , 16, 1175-1181	0.1	
37	High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. <i>Cancer</i> , <b>2010</b> , 116, 4139-46	6.4	99
36	Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. <i>Melanoma Research</i> , <b>2010</b> , 20, 240-6	3.3	39
35	Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3496-502	2.2	29
34	Früherkennung und Prävention des malignen Melanoms. <i>Onkologe</i> , <b>2009</b> , 15, 738-743	0.1	
33	Clinical course and prognostic factors of Merkel cell carcinoma of the skin. <i>British Journal of Dermatology</i> , <b>2009</b> , 161, 90-4	4	32
32	Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. <i>Clinical and Experimental Dermatology</i> , <b>2009</b> , 34, 240-2	1.8	9
31	Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 863-8	4.5	18
30	Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 498-507	5	219
29	Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. <i>Melanoma Research</i> , <b>2009</b> , 19, 50-7	3.3	44
28	Cutaneous Metastases of Melanoma: New Treatment Options <b>2009</b> , 591-598		
27	Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1195-201	10.3	99
26	Aktuelle Therapie des malignen Melanoms. <i>Aktuelle Dermatologie</i> , <b>2008</b> , 34, 465-471	0.1	
25	Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 180-8	5	166
24	Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. <i>Melanoma Research</i> , <b>2008</b> , 18, 353-8	3.3	18
23	Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. <i>Melanoma Research</i> , <b>2008</b> , 18, 274-8	3.3	71
22	Age and gender are significant independent predictors of survival in primary cutaneous melanoma. <i>Cancer</i> , <b>2008</b> , 112, 1795-804	6.4	176

21	Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of $\geq 1.5$ mm tumor thickness: A randomized phase III DeCOG trial. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 9032-9032	2.2	4
20	Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed?. <i>Cancer</i> , <b>2007</b> , 109, 1174-82	6.4	36
19	Kutanes Melanom. <i>Onkologe</i> , <b>2007</b> , 13, 745-758	0.1	
18	Diagnosis and treatment of cutaneous melanoma: state of the art 2006. <i>Melanoma Research</i> , <b>2007</b> , 17, 117-27	3.3	157
17	Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 557-64	7.5	150
16	A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 57, 616-21	4.5	63
15	The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. <i>Cancer</i> , <b>2006</b> , 107, 1331-9	6.4	96
14	Malignant melanoma: classification and staging of malignant melanoma. <i>Frontiers of Radiation Therapy and Oncology</i> , <b>2006</b> , 39, 149-158		3
13	Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 342-50	7.5	85
12	Metastatic glucagonoma: treatment with liver transplantation. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, 344-7	4.5	14
11	Plasma cell-rich rejection processes in renal transplantation: morphology and prognostic relevance. <i>Transplantation</i> , <b>2006</b> , 81, 986-91	1.8	47
10	A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 8044-8044	2.2	14
9	Imiquimod in the treatment of extensive recurrent lentigo maligna. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 51-2	4.5	32
8	Acquired perforating collagenosis in Hodgkin's disease. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 922	4.5	15
7	Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Cancer</i> , <b>2005</b> , 103, 616-24	6.4	79
6	Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3660-7	2.2	88
5	Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4376-83	2.2	36
4	Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma?. <i>Dermatology</i> , <b>2004</b> , 209, 249-50	4.4	14

3	Malignant blue naevus of the scalp. <i>Lancet Oncology, The</i> , <b>2004</b> , 5, 429	21.7	
2	Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1620-6	8.7	145
1	Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. <i>Lancet Oncology, The</i> , <b>2003</b> , 4, 748-59	21.7	247